Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Open access

Abstract

BACKGROUND: Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at codons 12 and 13. In colorectal cancer, the presence of any mutant KRas amino acid substitution is a negative predictor of patient response to targeted therapy. However, in non-small cell lung cancer (NSCLC), the evidence that KRAS mutation is a predictive factor is conflicting. METHODS: We used data from a molecularly targeted clinical trial for 215 patients with tissues available out of 268 evaluable patients with refractory NSCLC to examine associations between specific mutant KRas proteins and progression-free survival and tumor gene expression. Transcriptome microarray studies of patient tumor samples and reverse-phase protein array studies of a panel of 67 NSCLC cell lines with known substitutions in KRas and in immortalized human bronchial epithelial cells stably expressing different mutant KRas proteins were used to investigate signaling pathway activation. Molecular modeling was used to study the conformations of wild-type and mutant KRas proteins. Kaplan-Meier curves and Cox regression were used to analyze survival data. All statistical tests were two-sided. RESULTS: Patients whose tumors had either mutant KRas-Gly12Cys or mutant KRas-Gly12Val had worse progression-free survival compared with patients whose tumors had other mutant KRas proteins or wild-type KRas (P = .046, median survival = 1.84 months) compared with all other mutant KRas (median survival = 3.35 months) or wild-type KRas (median survival = 1.95 months). NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation. Molecular modeling studies showed that different conformations imposed by mutant KRas may lead to altered association with downstream signaling transducers. CONCLUSIONS: Not all mutant KRas proteins affect patient survival or downstream signaling in a similar way. The heterogeneous behavior of mutant KRas proteins implies that therapeutic interventions may need to take into account the specific mutant KRas expressed by the tumor.

Overview

Integrity signals

Registry

Crossref · 10.1093/jnci/djr523

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 31 references

Cited by

See all 532

Metadata

Authors
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., Diao, L., Coombes, K. R., Chen, L., Zhang, S., Abdelmelek, M. F., Tang, X., Papadimitrakopoulou, V., Minna, J. D., Lippman, S. M., Hong, W. K., Herbst, R. S., Wistuba, I. I., Heymach, J. V., & Powis, G.
Affiliations
Harold C. Simmons Comprehensive Cancer Center (US)
Venue
JNCI: Journal of the National Cancer Institute
Published
2012-01-13
Volume
104
Issue
3
Pages
228-239
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2166923287
Cited by
532
References
31
Citations by year
2026: 23 · 2025: 32 · 2024: 41 · 2023: 32 · 2022: 45 · 2021: 49 · 2020: 40 · 2019: 38 · 2018: 37 · 2017: 25 · 2016: 42 · 2015: 48 · 2014: 31 · 2013: 28 · 2012: 21
FWCI
32.99
Type
journal article
Language
en
Open access
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • U.S. Department of Defense (W81XWH, W81XWH-6-1-0303)
  • National Institutes of Health (W81XWH, CA- 016672)
  • University of Texas MD Anderson Cancer Center ((CA016672), P30-CA-016672)
  • National Cancer Institute (R01CA155196, R01CA160398, CA155196, P50CA070907, CA160398, P30CA016672)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
KRAS mutation, non-small cell lung cancer, progression-free survival, predictive biomarkers, PI3K signaling, MEK signaling, Akt activation, protein conformation, targeted therapy, colorectal cancer
MeSH terms
Aspartic Acid, Carcinoma, Non-Small-Cell Lung, Cysteine, Genetic Vectors, Glycine, Humans, Lung Neoplasms, Mutation, Genes, ras, Valine, Immunoblotting, Signal Transduction, Gene Expression Regulation, Neoplastic, Randomized Controlled Trials as Topic, Lentivirus, Treatment Outcome, Clinical Trials, Phase II as Topic, Disease-Free Survival, Gene Expression Profiling, Cell Line, Tumor, Microarray Analysis, Immunoprecipitation, Proto-Oncogene Proteins c-akt, Kaplan-Meier Estimate, TOR Serine-Threonine Kinases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. https://app.cochat.ai/papers/10.1093/jnci/djr523
The paper
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., Diao, L., Coombes, K. R., Chen, L., Zhang, S., Abdelmelek, M. F., Tang, X., Papadimitrakopoulou, V., Minna, J. D., Lippman, S. M., . . . Powis, G. (2012). Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djr523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.